Last checked at 16 Apr 2024 09:48
LONDON BROKER RATINGS: RBC raises Admiral; Barclays cuts Phoenix Group
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades15,672
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
10,878.00
Bid:
10,886.00
Ask:
10,888.00
Change:
-146.00 (-1.32%)
Spread:
2.00 (0.018%)
Open:
10,882.00
High:
10,966.00
Low:
10,822.00
Prev. Close:
11,024.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca signs major deal with Grunenthal over Zurampic
Thu, 02nd Jun 2016 07:08
(ShareCast News) - Pharmaceutical and biologics company AstraZeneca announced on Thursday that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America.The FTSE 100 firm received approval from the European Medicines Agency in February for Zurampic, for the adjunctive treatment of hyperuricemia, or excess of uric acid in the blood, in adult patients with uncontrolled gout.Under the terms of the deal, Grünenthal will acquire the exclusive rights to Zurampic in all 28 European Union member states, Switzerland, Iceland, Norway and Lichtenstein, and in all Latin American countries including Mexico, the Dominican Republic and Cuba.Additionally, Grünenthal will obtain the exclusive rights to a fixed-dose combination of lesinurad and allopurinol in those markets - the combination is currently in clinical trials.Grünenthal will submit the fixed-dose combination programme or regulatory review, and will pay AstraZeneca up to $230m in sales and other related milestones over the lifetime of the contract under the terms of the agreement.Grünenthal will also pay tiered, low double-digit royalties on annual product sales, while AstraZeneca will initially manufacture and supply Zurampic to Grünenthal and will undertake the European post-approval commitment on Grünenthal's behalf.From 1 October 2021, Grünenthal has the option to take over manufacturing from AstraZeneca."Grünenthal has an established presence across European and Latin American markets and extensive expertise in inflammatory diseases," said AstraZeneca executive vice president, global product and portfolio strategy Luke Miels."This agreement allows us to further focus our resources on our strategic priorities."Grünenthal CEO Prof Dr Eric-Paul Pâques said the company was highly committed to the research, development and commercialisation of innovative therapies."Zurampic is a strong addition to our existing portfolio of innovative therapies in the areas of inflammatory diseases and chronic pain."We will thus use our capabilities to provide patients in our markets with this innovative new medicine to better control their condition," Prof Dr Pâques explained.
More News
16 Apr 2024 09:30
Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains
INGELHEIM, Germany, April 16 (Reuters) - Boehringer Ingelheim on Tuesday overtook Bayer as Germany's largest drugmaker when the unlisted company reported a currency-adjusted gain in 2023 pharmaceutical sales of 10.3% to 20.8 billion euros ($22.11 billion).
Read more16 Apr 2024 08:39
AstraZeneca's hails Imfinzi survival data on cancer form
(Alliance News) - AstraZeneca PLC on Tuesday said that its immunotherapy Imfinzi showed positive survival rate in people with advanced biliary tract cancer.
Read more12 Apr 2024 12:55
EU regulator rules out link between weight-loss drugs and suicidal thoughts
April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.
Read more11 Apr 2024 18:51
AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
Policy approved with two-third of votes in favour
*Read more11 Apr 2024 17:13
FTSE 100 edges lower as financials drag
Lok'nStore surges to all-time high after buyout by Shurgard
*Read more11 Apr 2024 17:07
Banks weigh down Europe's STOXX 600 after ECB signals rate cuts
Outlook hike sends Ambu shares up
*Read more11 Apr 2024 15:56
London close: Stocks finish lower as ECB stands pat
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.
Read more11 Apr 2024 11:50
LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision
(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.
Read more11 Apr 2024 08:56
TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023
(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.
Read more11 Apr 2024 08:54
LONDON MARKET OPEN: European markets mixed ahead of ECB decision
(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.
Read more11 Apr 2024 07:49
LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.
Read more11 Apr 2024 07:20
AstraZeneca to hike 2024 dividend by 7%
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.
Read more8 Apr 2024 08:36
TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris
(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.
Read more8 Apr 2024 07:43
LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack
(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.
Read more